[go: up one dir, main page]

MX2008000178A - Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia. - Google Patents

Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.

Info

Publication number
MX2008000178A
MX2008000178A MX2008000178A MX2008000178A MX2008000178A MX 2008000178 A MX2008000178 A MX 2008000178A MX 2008000178 A MX2008000178 A MX 2008000178A MX 2008000178 A MX2008000178 A MX 2008000178A MX 2008000178 A MX2008000178 A MX 2008000178A
Authority
MX
Mexico
Prior art keywords
dementia
treatment
fatty acids
related conditions
polyunsaturated fatty
Prior art date
Application number
MX2008000178A
Other languages
English (en)
Other versions
MX336435B (es
Inventor
Lorie A Ellis
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Publication of MX2008000178A publication Critical patent/MX2008000178A/es
Publication of MX336435B publication Critical patent/MX336435B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen composiciones y metodos para tratar o prevenir demencia y condiciones relacionadas con pre-demencia y/o sintomas o caracteristicas de tales condiciones.
MX2008000178A 2005-07-08 2006-07-07 Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia. MX336435B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69791105P 2005-07-08 2005-07-08
US77914506P 2006-03-02 2006-03-02
PCT/US2006/026331 WO2007008586A2 (en) 2005-07-08 2006-07-07 Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions

Publications (2)

Publication Number Publication Date
MX2008000178A true MX2008000178A (es) 2008-04-07
MX336435B MX336435B (es) 2016-01-19

Family

ID=37637739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008000178A MX336435B (es) 2005-07-08 2006-07-07 Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.

Country Status (12)

Country Link
US (3) US20070032548A1 (es)
EP (1) EP1904049B1 (es)
JP (4) JP2009502745A (es)
KR (5) KR101965124B1 (es)
CN (2) CN103211807A (es)
AU (1) AU2006269405B2 (es)
BR (1) BRPI0613358A8 (es)
CA (1) CA2614473C (es)
ES (1) ES2617577T3 (es)
MX (1) MX336435B (es)
RU (1) RU2444356C2 (es)
WO (1) WO2007008586A2 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI120720B (fi) * 2006-06-16 2010-02-15 Neurofood Ab Oy Maitopohjaisia elintarvikkeita, jotka sisältävät keskushermoston lipidejä
CA2682497C (en) 2007-04-05 2017-08-08 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
KR101409115B1 (ko) 2007-06-08 2014-06-17 엘지전자 주식회사 다중 안테나 시스템에서 가중치 정보 전송 방법
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
CA2692309C (en) * 2007-06-26 2016-08-16 N.V. Nutricia Improving memory in subjects with mini-mental state examination of 24-26
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
JP5306345B2 (ja) * 2007-07-26 2013-10-02 フェノメノーム ディスカバリーズ インク 自閉症スペクトラム障害の診断、リスク評価、及びモニタリングを行うための方法
WO2009055818A1 (en) * 2007-10-25 2009-04-30 Research Foundation Of State University Of New York A spectral biomarker and algorithm for the identification and detection of neural stem and progenitor cells and their use in studying mammalian brains
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2211881A4 (en) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine COMPOSITIONS AND METHOD FOR THE PREVENTION AND TREATMENT OF SEDUCTIVES OF MAMMALS
WO2009057994A1 (en) 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
MX2010006829A (es) 2007-12-20 2010-09-30 Nutricia Nv Producto que contiene nucleotidos/nucleosidos liquidos.
EP2224930B1 (en) 2008-01-04 2016-06-15 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions
WO2009158148A1 (en) * 2008-05-30 2009-12-30 The Trustees Of Columbia University In The City Of New York Methods for diagnosis and treatment of neurodegenerative diseases or disorders
CN104042600A (zh) * 2009-02-02 2014-09-17 帝斯曼知识产权资产有限公司 改善认知功能和降低心率的方法
JP4598162B2 (ja) * 2009-02-05 2010-12-15 パナソニック株式会社 撮像処理装置
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
KR20120014253A (ko) * 2009-04-14 2012-02-16 젠야쿠코교가부시키가이샤 프로-ａｄａｍ10 세크레타제 및/또는 베타 세크레타제 수치를 감소시키는 방법
EP2429317B2 (en) * 2009-04-17 2019-02-20 Natac Pharma, S.L. Compositions rich in omega-3 fatty acids with a low content in phytanic acid
US20110177061A1 (en) 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
US20110082205A1 (en) 2009-10-01 2011-04-07 Panker Cynthia A Docosahexaenoic Acid Gel Caps
US20110257267A1 (en) * 2009-10-13 2011-10-20 Kevin Hadley Reducing the Risk of Pathological Effects of Traumatic Brain Injury
JP5934102B2 (ja) 2009-10-30 2016-06-15 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ誘導体による酸化ストレス障害の緩和
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
KR102014526B1 (ko) 2011-04-26 2019-08-26 레트로토프 인코포레이티드 Ｐｕｆａ 산화와 관련된 장애
US10058522B2 (en) 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
CA2834342C (en) 2011-04-26 2021-08-31 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
AU2012249917B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
PT2579042E (pt) * 2011-10-04 2014-09-09 Affiris Ag Método para detecção de anticorpos específicos para a numa amostra biológica.
EP3777547A1 (en) 2011-11-01 2021-02-17 DSM IP Assets B.V. Oxidatively stable polyunsaturated fatty acid containing oil
US20150018320A1 (en) * 2012-02-29 2015-01-15 B. Braun Melsungen Ag Hormone Containing Emulsion Comprising Krill Phospholipids
JP5986440B2 (ja) * 2012-07-05 2016-09-06 国立医薬品食品衛生研究所長 アルツハイマー病の発症を予測する方法
US20140203176A1 (en) * 2013-01-23 2014-07-24 Dow Agrosciences Llc Systems and methods for real-time sampling and analysis of biomolecules beneath the surface of biological tissue
CN103217463A (zh) * 2013-03-14 2013-07-24 中南大学 一种用于bace1抑制剂筛选的电化学方法
CN105163731B (zh) * 2013-07-10 2017-10-31 狮王株式会社 内服组合物
CN104368002B (zh) * 2014-10-17 2019-01-08 中国人民解放军军事医学科学院毒物药物研究所 用于治疗痴呆或认知功能障碍的联合用药物
WO2016112174A2 (en) * 2015-01-08 2016-07-14 The Trustees Of The University Of Pennsylvania Biomarkers of Sleep Deprivation and Cognitive Impairment
KR20170025977A (ko) * 2015-08-31 2017-03-08 재단법인차세대융합기술연구원 옥시리스 마리나로부터 분리된 신규 화합물
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
CA3005983A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
IL283779B (en) 2015-11-24 2022-09-01 Massachusetts Inst Technology Systems and methods for preventing, alleviating and/or treating dementia
BR112018017133B1 (pt) * 2016-02-22 2023-01-31 Newtricious B.V. Composição para prevenção ou tratamento de doenças neurodegenerativas
AU2017363200B2 (en) 2016-11-17 2021-11-18 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via visual stimulation
CN106666745A (zh) * 2016-12-22 2017-05-17 徐晓飞 一种含姜黄素和dha的组合物及应用
CN106617064A (zh) * 2016-12-22 2017-05-10 徐晓飞 一种含姜黄素和ω‑3多不饱和脂肪酸的组合物及其应用
WO2018161211A1 (en) * 2017-03-06 2018-09-13 Nippon Zoki Pharmaceutical Co., Ltd. INHIBITING OR ALLEVIATING AGENT FOR Aβ-INDUCED DAMAGE
US11065288B2 (en) 2017-09-29 2021-07-20 Kinjirushi Co., Ltd. Neuron activator
CA3078704A1 (en) 2017-10-10 2019-04-18 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia
US10960225B2 (en) 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
BR112022013296A2 (pt) * 2020-01-03 2022-09-06 Biosearch S A Composição para uso no tratamento de transtornos cognitivos
US11779910B2 (en) 2020-02-21 2023-10-10 Biojiva Llc Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
KR102466479B1 (ko) 2020-03-30 2022-11-15 주식회사 뷰브레인헬스케어 타우 단백질 축적 예측 장치 및 이를 이용한 타우 단백질 축적 예측 방법
CN114680336A (zh) * 2020-12-30 2022-07-01 云南汉盟制药有限公司 一种含火麻仁不饱和脂肪酸的滴剂及其制备方法
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
CN112798727B (zh) * 2021-04-09 2021-07-06 宝枫生物科技（北京）有限公司 用于诊断脑白质病变的生物标志物f7及其应用
KR20240148365A (ko) * 2022-02-11 2024-10-11 바이오지바 엘엘씨 망막 산화 질환의 치료에 대한 환자 반응을 모니터링하기 위한 방법

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5408326A (en) * 1993-04-28 1995-04-18 Shell Oil Company Dual-wavelength absorption detector adapted for continuous-flow detection
US5403826A (en) * 1993-05-28 1995-04-04 Abbott Laboratories Nutritional product for persons infected with human immunodeficiency virus
ATE181745T1 (de) 1994-08-16 1999-07-15 Frische Gmbh Verfahren zur gewinnung von nicht wasserlöslichen, nativen produkten aus nativen stoffgemengen mit hilfe der zentrifugalkraft
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
ATE347607T1 (de) * 1996-07-23 2006-12-15 Nagase Chemtex Corp Verfahren zur herstellung von decosahexaensäure und decosapentsäure
KR20060061409A (ko) * 1996-10-11 2006-06-07 스카리스타 리미티드 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
WO2000051444A1 (en) * 1999-03-04 2000-09-08 Suntory Limited Utilization of material containing docosapentaenoic acid
CA2311974A1 (en) * 1999-06-28 2000-12-28 Nisshin Flour Milling Co., Ltd. Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
US6395778B1 (en) * 2000-01-11 2002-05-28 Omegatech, Inc. Process for making an enriched mixture of polyunsaturated fatty acid esters
PT1272049E (pt) 2000-04-12 2010-02-15 Gea Westfalia Separator Gmbh Método para fraccionamento de matérias-primas nativas contendo óleo e lípidos polares utilizando álcool e centrifugação
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
JP4629834B2 (ja) * 2000-05-12 2011-02-09 備前化成株式会社 神経細胞賦活剤およびその利用
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
AU2003272738B2 (en) * 2002-09-27 2010-04-01 Martek Biosciences Corporation Docosahexaenoic acid for improved glycemic control
EP2283838A3 (en) * 2002-09-27 2011-04-20 Martek Biosciences Corporation Docosahexaenoic acid for treating subclinical inflammation
US20050265983A1 (en) * 2002-11-17 2005-12-01 Eldad Melamed Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US7935365B2 (en) * 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
EP1713463A4 (en) * 2004-01-19 2009-03-18 Martek Biosciences Corp REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES
US20060020031A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
JP2008520739A (ja) * 2004-11-19 2008-06-19 マーテック・バイオサイエンシーズ・コーポレーション 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
DE102005003625A1 (de) * 2005-01-26 2006-07-27 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Verfahren zur Herstellung einer DHA-haltigen Fettsäure-Zusammensetzung
US20060270739A1 (en) * 2005-04-28 2006-11-30 Trustees Of Tufts College Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation
JP2008540394A (ja) * 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
AU2006251562B2 (en) * 2005-05-23 2012-03-22 Massachusetts Institute Of Technology Compositions containing PUFA and methods of use thereof
US20070042953A1 (en) * 2005-08-16 2007-02-22 Bazan Nicolas G Antiepileptogenic complex of albumin with docosahexaenoate
RU2400102C2 (ru) * 2005-08-26 2010-09-27 Нестек С.А. Композиция для лечения, замедления или предотвращения у животного слабоумия, старения мозга, когнитивного нарушения, инсульта или болезни альцгеймера и ее применение (варианты)
WO2009006317A1 (en) * 2007-06-29 2009-01-08 Martek Biosciences Corporation Production and purification of esters of polyunsaturated fatty acids

Also Published As

Publication number Publication date
AU2006269405A1 (en) 2007-01-18
WO2007008586A3 (en) 2007-04-12
AU2006269405B2 (en) 2013-01-17
KR20130101596A (ko) 2013-09-13
JP2018021078A (ja) 2018-02-08
KR101965124B1 (ko) 2019-04-02
KR20160116351A (ko) 2016-10-07
CN103211807A (zh) 2013-07-24
JP2013056900A (ja) 2013-03-28
JP2015147775A (ja) 2015-08-20
US20070032548A1 (en) 2007-02-08
CN101262863B (zh) 2016-08-31
BRPI0613358A2 (pt) 2011-01-04
KR20190014122A (ko) 2019-02-11
US20150119464A1 (en) 2015-04-30
CN101262863A (zh) 2008-09-10
KR20080027384A (ko) 2008-03-26
MX336435B (es) 2016-01-19
BRPI0613358A8 (pt) 2017-12-26
EP1904049B1 (en) 2016-12-07
WO2007008586A2 (en) 2007-01-18
CA2614473A1 (en) 2007-01-18
EP1904049A2 (en) 2008-04-02
ES2617577T3 (es) 2017-06-19
JP2009502745A (ja) 2009-01-29
US20110218242A1 (en) 2011-09-08
EP1904049A4 (en) 2012-08-01
RU2008104697A (ru) 2009-08-20
KR20180026556A (ko) 2018-03-12
CA2614473C (en) 2016-05-03
RU2444356C2 (ru) 2012-03-10
KR101870626B1 (ko) 2018-06-26

Similar Documents

Publication Publication Date Title
MX336435B (es) Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
MX342128B (es) Compuestos farmaceuticos.
WO2006024018A3 (en) Compositions for treating nociceptive pain
NO20070561L (no) Sammensetninger og fremgangsmater for a behandle oyesykdommer og tilstander.
MX338235B (es) Microorganismos eucarioticos para producir lipidos y antioxidantes.
MX2008011872A (es) Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.
WO2007001851A3 (en) Compositions and methods for the diagnosis and treatment of tumor
MX2013006598A (es) Inhibidores de la amida hidrolasa de acidos grasos (faah).
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
UA96442C2 (ru) Fad-2 мутанты и растения с высоким содержанием олеиновой кислоты
MY192633A (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
ZA200702322B (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200901037B (en) Pyrimidone compounds as GSK-3 inhibitors
WO2007099459A3 (en) Fad-2 mutants and high oleic plants
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
AU2010306870A8 (en) Reducing the risk of pathological effects of traumatic brain injury
WO2008092099A3 (en) Compositions and methods for treating hematopoietic malignancies
WO2007136857A3 (en) Hox compositions and methods
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility
WO2007117419A3 (en) Methods and compositions relating to post-prolyl cleaving enzyme inhibitors
IN2015DN03331A (es)
WO2010065861A3 (en) Inhibitors of bace 1 and methods for treating alzheimer's disease
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.